Notice of Interim Results

RNS Number : 9498B

Avacta Group PLC

11 March 2014

 



Avacta Group plc

("Avacta" or the "Group")

Notice of Interim Results

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, will announce its Interim Results, for the six month period ended 31 January 2014, on Wednesday 23^rd April 2014.

An analyst briefing given by Alastair Smith, Chief Executive Officer, Craig Slater, Chief Operating Officer and Tim Sykes, Chief Financial Officer will be held at 9.30am on the day at a central location in the City of London to be confirmed. Analysts who wish to attend should contact Lianne Cawthorne on [phone] or email [e-mail] to register.

Enquiries:

Avacta Group plc		Tel:  [phone]
Alastair Smith, Chief Executive Officer		www.avacta.com
Tim Sykes, Chief Financial Officer
Numis Securities Limited		Tel:  [phone]
Michael Meade / Freddie Barnfield - Nominated Adviser		www.numiscorp.com
James Black - Corporate Broking
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Avacta Group plc - www.avacta.com

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

Avacta Analytical www.avactaanalytical.com	High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.
Avacta Animal Health www.avactaanimalhealth.com	Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.
Avacta Life Sciences www.avactalifesciences.com	Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

END

 

 

NORURUNRSWAOAAR